Skip to main content
British Medical Journal logoLink to British Medical Journal
. 1973 Jan 6;1(5844):13–14. doi: 10.1136/bmj.1.5844.13

Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose Levels

H W C Ward
PMCID: PMC1588574  PMID: 4567104

Abstract

Tamoxifen (ICI 46474) was given by mouth to patients with advanced, recurrent, or metastatic breast carcinoma. At a dosage of 10 mg twice daily 60% of patients showed arrest or reversal of tumour growth. At a dosage of 20 mg twice daily 77% showed arrest or reversal of tumour growth. Side effects were usually trivial and their incidence was the same at both dose levels. No patients showed virilization of fluid retention.

Full text

PDF
13

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cole M. P., Jones C. T., Todd I. D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971 Jun;25(2):270–275. doi: 10.1038/bjc.1971.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. HERBST A. L., GRIFFITHS C. T., KISTNER R. W. CLOMIPHENE CITRATE (NSC-35770) IN DISSEMINATED MAMMARY CARCINOMA. Cancer Chemother Rep. 1964 Dec;43:39–41. [PubMed] [Google Scholar]
  3. KISTNER R. W., SMITH O. W. Observations on the use of a non-steroidal estrogen antagonist: MER-25. Surg Forum. 1960;10:725–729. [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES